This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Navidea To Collaborate With University Of Alabama–Birmingham On Clinical Study Evaluating The RIGS™ Monoclonal Antibody Targeting Agent

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced it will collaborate with investigators at the University of Alabama at Birmingham (UAB) on a clinical study to evaluate the safety and activity of a radiolabeled, humanized monoclonal antibody (Mab) from its RIGS™ Monoclonal Antibody Targeting technology. The study will evaluate up to 20 patients with colorectal cancer (CRC) by administering the RIGS tumor-specific radiolabeled, CH2 domain-deleted, anti-TAG-72 Mab-targeting agent and assessing by SPECT/CT imaging for the presence of liver metastasis. The co-principle investigators for the study are Andres Forero, MD, the O'Neal-Sokol Breast Cancer Research Foundation of Alabama Endowed Professorship, Director, Protocol/Data Management Shared Facility, and Co-Leader, Experimental Therapeutics, UAB Comprehensive Cancer Center; Kurt Zinn, DVM, MS, PhD, Director, Advanced Medical Imaging Research, UAB; and Janis P. O’Malley, MD, Director, Division of Molecular Imaging and Therapeutics, and Professor of Radiology, UAB School of Medicine. Investigators at UAB have published extensively on the use of TAG-72 targeted monoclonal antibodies in the cancer setting.

“The detection of metastasis of colorectal cancer to the liver has had less than acceptable sensitivity and low specificity using traditional CT. There is the need to find better modalities to evaluate the liver at the time of the initial diagnosis of CRC,” commented Dr. Forero. “We are looking forward to working with Navidea to evaluate this tumor-specific imaging agent that may benefit surgeons in effectively locating cancerous tissues leading to better patient outcomes.”

The study is to be funded in part through the Company’s Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI), National Institutes of Health (NIH) announced in 2012. The SBIR grant has the potential for grant money up to a total of $1.5M over three years if fully funded. The first-year Phase I funding of $315,000, which has already been approved, focused on completing preclinical bridging activities using the CH2 domain-deleted, anti-TAG-72 Mab and preparing a standardized clinical trial protocol. Phase II funding of up to $1.2M will be used in support the clinical study and is contingent upon meeting certain Phase I success criteria, including Institutional Review Board (IRB) approval of the clinical trial protocol. Commencement of the clinical study is also contingent upon completing certain antibody stability and quality tests currently in process.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.75 -1.10%
FB $117.53 0.69%
GOOG $693.00 0.29%
TSLA $240.75 -2.80%
YHOO $36.61 0.06%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.87 -9.94 -0.48%
NASDAQ 4,775.8150 -29.4760 -0.61%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs